Lenalidomide

Type: Keyphrase

Name: Lenalidomide

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Blood cancers perifosine

AbstractAn important target in cancer treatment is the serine/threonine specific protein kinase Akt, which is involved in the pathway that inhibits apoptosis An important target in cancer treatment is the serine/threonine specific protein kinase Akt, ... [Published Manufacturing Chemist - May 22 2013]

Entities: perifosine, Bortezomib, partial response, dexamethasone

First reported May 18 2013 - Updated May 18 2013 - 1 reports

Patients get ‘too strong’ cancer drug due to cost

Patients battling a form of bone marrow cancer are being given a medicine that is too strong because prices for lower doses exceed the Government’s payment limit, Times of Malta has learnt.As a consequence, patients treated with Revlimid are left weakened ... [Published Times of Malta - May 18 2013]

Entities: Lenalidomide, antineoplastic, Patient

First reported May 16 2013 - Updated May 16 2013 - 1 reports

bendamustine

Novel agents for chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is a heterogeneous group of B-cell neoplasm. CLL is typically sensitive to a variety of cytotoxic agents, but relapse frequently occurs with conventional approaches.The treatment of CLL is evolving rapidly with the introduction ... [Published 7thSpace - May 16 2013]

Entities: chronic lymphocytic leukemia, bendamustine, Dasatinib, Lenalidomide

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Latest treatments extending survival for multiple myeloma patients

Recent "Spotlight On" report highlights next generation drugsMultiple myeloma is the second most common hematological cancer worldwide, with an estimated 22,000 new cases and over 10,000 deaths expected in the U.S. in 2013 and an approximately equivalent ... [Published Thomson Reuters - May 15 2013]

Entities: Multiple Myeloma, treatments, Velcade, Patient

First reported May 14 2013 - Updated May 14 2013 - 1 reports

In Relapsed/Refractory Multiple Myeloma, Thought Leaders Are Optimistic that the Combination of Carfilzomib, Lenalidomid

/PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European hematological oncologists indicate that overall survival is the factor that most ... [Published NewsBlaze - May 14 2013]

Entities: Multiple Myeloma, Carfilzomib, Lenalidomide, dexamethasone, oncologist

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Celgene Corporation

Concert in tune with Celegene for $300 million deal

LEXINGTON, Mass. announced May 6 that it had entered into a strategic collaboration with Summit, N.J.-based Celgene Corp. that is focused on the development of deuterium-modified compounds targeting cancer and inflammation. The collaboration will initially ... [Published Drug Discovery News - May 08 2013]

Entities: Celgene Corporation, Drugs, Roger Tung, Inflammation

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Celgene’s Revlimid Approaches FDA Decision For MCL Indication

Celgene Corporation (NASDAQ: CELG) remains just under its 52-week high of $128.52 per share as the market continues to reflect the company’s financial and developmental success halfway throughout the new year.The drug developer has a huge and highly diversified ... [Published BioMedReports - May 07 2013]

Entities: Celgene Corporation, Drugs, Abraxane, Lenalidomide

First reported May 04 2013 - Updated May 04 2013 - 1 reports

Highlights from the European Congress on Hematologic Malignancies

Maria-Victoria Mateos, MD, PhD, consultant physician from the hematology department at University Hospital of Salamanca, Spain, focused on smoldering (asymptomatic) multiple myeloma, specifically advocating early intervention: “The earlier the intervention ... [Published Oncology Times - May 04 2013]

Entities: Lenalidomide, Patient, Ibrutinib, dexamethasone

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Secondary Cancer Risk Found With Multiple Myeloma Maintenance Therapies

Patients with multiple myeloma may develop myelodysplastic syndrome-associated cytogenetic abnormalities (MDS-CA) after treatment with maintenance lenalidomide or thalidomide after melphalan exposure, increasing the risk for clinical MDS/acute leukemia, ... [Published Cancernetwork.com - May 02 2013]

Entities: Multiple Myeloma, Lenalidomide, Thalidomide, Patient

First reported May 01 2013 - Updated May 01 2013 - 2 reports

Celgene International Sarl Reports European Medicines Agency's Opinion for Revlimid

Celgene International Sarl announced the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for Revlimid for the treatment of patients with transfusion-dependent anemia due to low or intermediate-1-risk ... [Published Individual.com - May 01 2013]

Entities: Lenalidomide, dexamethasone, Patient

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma

Multiple myeloma is a malignancy of B cells characterized by accumulation of abnormal plasma cells in the bone marrow. In the past 20 years, the use of high-dose therapies and novel agents has resulted in significant and meaningful improvements in survival. ... [Published The Oncologist - Apr 30 2013]

Entities: Multiple Myeloma, consolidation therapy, busulfan, Patient, Autologous Stem Cell Transplant

First reported Apr 27 2013 - Updated Apr 27 2013 - 1 reports

EMA opinions: good news for Astellas, Roche and Vivus

The latest set of opinions from advisors to the sees five new medicines and two generics recommended for approval.First up, the agency's Committee for Human Medicinal Products (CHMP) has issued a positive recommendation on Astellas and Medivation's Xtandi ... [Published Pharma Times - Apr 27 2013]

Entities: Astellas Pharma Inc, Roche Holding AG, NUEDEXTA, chondrocyte, Quinidine

Quotes

...on current treatment options for patients with cancer," said Gary Gordon, M D , divisional vice president, oncology clinical development, AbbVie. "With our pioneering research, we are breaking new ground in some of the most widespread and difficult-to-treat cancers."

ABBVIE INC: AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society o ... [Published 4 Traders - May 15 2013]

...settings," said Pablo Cagnoni, M D , Executive Vice President, Global Research & Development and Technical Operations at Onyx Pharmaceuticals. "We are committed to exploring therapies in difficult-to-treat cancers for patients who have limited treatment options."

ONYX PHARMACEUTICALS, INC.: Onyx Pharmaceuticals Announces Data Presentations at 49th American So ... [Published 4 Traders - May 15 2013]

...Revlimid to patients with MDS throughout the EU who have an isolated del(5q) cytogenic abnormality," said Alan Colowick, President of Celgene EMEA. "Following the final decision by the European Commission within the next few months, we can begin the work of partnering with our many stakeholders to ensure patients have access to this new treatment option."

Celgene International Sarl Reports European Medicines Agency's Opinion for Revlimid [Published Individual.com - May 01 2013]

"We haven't done gut imaging, so we'd be learning, too" came the reply, suggesting co-development potential

bwt04292013 [Published Pharmacy Choice - Apr 29 2013]

More Content

sort by: Date \| Relevance
Takeda Initiates TOURMALINE-MM2 Pivotal Phase 3... [Published Business Wire Health News - May 23 2013]
Blood cancers perifosine [Published Manufacturing Chemist - May 22 2013]
Cell Therapeutics, Inc. Presents at UBS Global ... [Published Seeking Alpha - May 22 2013]
Acetylon Pharmaceuticals to Present at UBS Glob... [Published Business Wire - May 20 2013]
Bristol-Myers Squibb Advances Leadership Positi... [Published Medicexchange.com - May 20 2013]
Patients get ‘too strong’ cancer drug due to cost [Published Times of Malta - May 18 2013]
Pharma Touting Phase II/III Wins in Run-Up to ASCO [Published Genetic Engineering News - May 16 2013]
Novel agents for chronic lymphocytic leukemia [Published 7thSpace - May 16 2013]
ABBVIE INC: AbbVie to Present Data on Investiga... [Published 4 Traders - May 15 2013]
ONYX PHARMACEUTICALS, INC.: Onyx Pharmaceutical... [Published 4 Traders - May 15 2013]
MMRGlobal Announces First Quarter 2013 Filing, ... [Published Marketwire - Breaking News Releases - May 15 2013]
AbbVie to Present Data on Investigational Anti-... [Published ADVFN UK - May 15 2013]
Latest treatments extending survival for multip... [Published Thomson Reuters - May 15 2013]
In Relapsed/Refractory Multiple Myeloma, Though... [Published NewsBlaze - May 14 2013]
In Relapsed/Refractory Multiple Myeloma, Though... [Published PR Newswire: General Business - May 14 2013]
Making the Case for Hiring an Onc Pharmacist [Published Pharmacy Practice News - May 09 2013]
Concert in tune with Celegene for $300 million ... [Published Drug Discovery News - May 08 2013]
Concert Pharma To Get $300M+ Per Drug in Celgen... [Published Oncology Business Review - May 07 2013]
Celgene’s Revlimid Approaches FDA Decision For ... [Published BioMedReports - May 07 2013]
Concert Pharma To Get $300M+ Per Drug in Celgen... [Published Xconomy - May 06 2013]
Bristol-Myers Has The Future Of Oncology Therapies [Published Seeking Alpha - May 05 2013]
Highlights from the European Congress on Hemato... [Published Oncology Times - May 04 2013]
Biotechnology: Strong Fundamentals Are The Basi... [Published Seeking Alpha - May 03 2013]
Secondary Cancer Risk Found With Multiple Myelo... [Published Cancernetwork.com - May 02 2013]
Celgene International Sarl Reports European Med... [Published Individual.com - May 01 2013]
Promising new agents for multiple myeloma [Published PMLive - May 01 2013]
Efficacy and Safety of Busulfan-Based Condition... [Published The Oncologist - Apr 30 2013]
bwt04292013 [Published Pharmacy Choice - Apr 29 2013]
Last Patient Enrolled in Bionor Pharma's Intern... [Published Reuters - Apr 29 2013]
EMA opinions: good news for Astellas, Roche and... [Published Pharma Times - Apr 27 2013]

sort by: Date \| Relevance
Pending EC decision: Revlimid, lenalidomide, Op... [Published Pending EC decisions and European Public Assess ... - Apr 26 2013]
Orphan designation: Lenalidomide, for the: Trea... [Published Orphan designations - Mar 01 2013]
4 Healthcare Stock Stories to Kick Off the Week [Published Wall St. Cheat Sheet - Feb 11 2013] Cellgene Corporation ( NASDAQ:CELG ): Closing price $100.02 Celgene said Friday that its Pomalyst brand therapy (pomalidomide) for patients suffering from multiple myeloma who have received a minimum of two prior therapies that included lenalidomide ...
Advances In Cancer 2012 [Published The Health Care Blog - Dec 28 2012] By JAMES SALWITZ, MD The 30,000 member American Society of Clinical Oncology is the world’s leading group of cancer physicians. ASCO is dedicated to curing cancer, supporting research, quality care, reducing treatment disparities and a heightened ...
Belden Acquires PPC and 4 Stocks Hitting 52-Wee... [Published Wall St. Cheat Sheet - Dec 12 2012] Belden Inc ( NYSE:BDC ) acquired privately held PPC, which is a top provider of broadband connectivity solutions based in Syracuse, New York, for $515.7 million. The acquisition should show improvements to Belden’s Broadcast Solutions platform, along ...